|
1
|
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
|
N Engl J Med
|
2011
|
28.99
|
|
2
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
|
N Engl J Med
|
2009
|
18.03
|
|
3
|
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
|
N Engl J Med
|
2015
|
10.86
|
|
4
|
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
|
Circulation
|
2012
|
4.10
|
|
5
|
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
|
Chest
|
2008
|
3.74
|
|
6
|
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
|
Arch Intern Med
|
2008
|
3.68
|
|
7
|
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
|
Lancet
|
2010
|
3.55
|
|
8
|
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
|
JAMA
|
2013
|
3.48
|
|
9
|
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.
|
Thromb Haemost
|
2011
|
3.16
|
|
10
|
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
|
Lancet
|
2010
|
2.98
|
|
11
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
12
|
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
|
Lancet Neurol
|
2012
|
2.77
|
|
13
|
Platelet inhibition with cangrelor in patients undergoing PCI.
|
N Engl J Med
|
2009
|
2.52
|
|
14
|
Antithrombotic therapy practices in US hospitals in an era of practice guidelines.
|
Arch Intern Med
|
2005
|
2.32
|
|
15
|
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
|
Eur Heart J
|
2011
|
2.31
|
|
16
|
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.
|
J Gen Intern Med
|
2006
|
2.21
|
|
17
|
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes.
|
Crit Care Med
|
2010
|
2.19
|
|
18
|
Sex differences in mortality following acute coronary syndromes.
|
JAMA
|
2009
|
2.17
|
|
19
|
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.17
|
|
20
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
|
J Am Coll Cardiol
|
2010
|
2.00
|
|
21
|
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
|
Stroke
|
2013
|
1.99
|
|
22
|
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
|
J Am Coll Cardiol
|
2005
|
1.97
|
|
23
|
Platelet function monitoring in patients with coronary artery disease.
|
J Am Coll Cardiol
|
2007
|
1.97
|
|
24
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
25
|
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.
|
Am Heart J
|
2003
|
1.67
|
|
26
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
|
Circulation
|
2012
|
1.66
|
|
27
|
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
|
Am Heart J
|
2011
|
1.65
|
|
28
|
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
|
J Am Coll Cardiol
|
2008
|
1.62
|
|
29
|
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.
|
J Am Coll Cardiol
|
2013
|
1.61
|
|
30
|
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
|
Circulation
|
2009
|
1.60
|
|
31
|
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary.
|
Circ Cardiovasc Interv
|
2011
|
1.56
|
|
32
|
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
|
Circulation
|
2014
|
1.54
|
|
33
|
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
|
Eur Heart J
|
2013
|
1.53
|
|
34
|
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
|
Int J Cardiol
|
2009
|
1.45
|
|
35
|
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
|
Eur Heart J
|
2012
|
1.45
|
|
36
|
Dronedarone and vitamin K antagonists: a review of drug-drug interactions.
|
Am Heart J
|
2010
|
1.43
|
|
37
|
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
|
EuroIntervention
|
2014
|
1.42
|
|
38
|
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
|
Am Heart J
|
2005
|
1.41
|
|
39
|
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
|
J Thromb Thrombolysis
|
2012
|
1.41
|
|
40
|
New anticoagulants--the path from discovery to clinical practice.
|
N Engl J Med
|
2008
|
1.39
|
|
41
|
Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
|
Am J Med
|
2008
|
1.37
|
|
42
|
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
|
Circulation
|
2006
|
1.35
|
|
43
|
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease.
|
J Am Coll Cardiol
|
2013
|
1.34
|
|
44
|
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2011
|
1.33
|
|
45
|
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.
|
Ann Pharmacother
|
2008
|
1.32
|
|
46
|
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
|
Circulation
|
2010
|
1.30
|
|
47
|
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
|
J Am Heart Assoc
|
2013
|
1.26
|
|
48
|
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
|
J Am Coll Cardiol
|
2010
|
1.26
|
|
49
|
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease.
|
Psychosom Med
|
2013
|
1.24
|
|
50
|
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
|
J Am Coll Cardiol
|
2013
|
1.23
|
|
51
|
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
|
Chest
|
2004
|
1.20
|
|
52
|
Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.
|
Arch Intern Med
|
2004
|
1.17
|
|
53
|
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
|
Circulation
|
2008
|
1.14
|
|
54
|
Antithrombotic therapy after myocardial infarction.
|
N Engl J Med
|
2002
|
1.12
|
|
55
|
G-protein-coupled receptors as signaling targets for antiplatelet therapy.
|
Arterioscler Thromb Vasc Biol
|
2008
|
1.10
|
|
56
|
Hypercoagulable states in cardiovascular disease.
|
Circulation
|
2008
|
1.09
|
|
57
|
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
|
Eur Heart J
|
2011
|
1.05
|
|
58
|
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
|
Chest
|
2008
|
1.05
|
|
59
|
Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.
|
Am Heart J
|
2007
|
1.04
|
|
60
|
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.
|
J Thromb Thrombolysis
|
2012
|
1.00
|
|
61
|
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
|
Circulation
|
2010
|
1.00
|
|
62
|
Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall.
|
Psychosom Med
|
2010
|
0.98
|
|
63
|
Cardiac rupture after myocardial infarction: new insights from murine models.
|
Cardiol Rev
|
2009
|
0.97
|
|
64
|
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Am Heart J
|
2012
|
0.96
|
|
65
|
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.96
|
|
66
|
The many faces of the contact pathway and their role in thrombosis.
|
J Thromb Thrombolysis
|
2011
|
0.96
|
|
67
|
Anticoagulant therapy during cardiopulmonary bypass.
|
J Thromb Thrombolysis
|
2008
|
0.95
|
|
68
|
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
|
Stroke
|
2014
|
0.94
|
|
69
|
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
|
Circ Heart Fail
|
2013
|
0.93
|
|
70
|
Factor IXa inhibitors as novel anticoagulants.
|
Arterioscler Thromb Vasc Biol
|
2007
|
0.92
|
|
71
|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
|
Platelets
|
2013
|
0.91
|
|
72
|
Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting.
|
Pharmacotherapy
|
2008
|
0.90
|
|
73
|
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
|
J Thromb Thrombolysis
|
2012
|
0.90
|
|
74
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
|
Clin Chem
|
2011
|
0.90
|
|
75
|
Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2012
|
0.88
|
|
76
|
The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.
|
J Thromb Thrombolysis
|
2003
|
0.88
|
|
77
|
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.
|
Am Heart J
|
2006
|
0.88
|
|
78
|
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.
|
Thromb Haemost
|
2012
|
0.88
|
|
79
|
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
|
Am J Cardiol
|
2011
|
0.88
|
|
80
|
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.
|
J Thromb Thrombolysis
|
2009
|
0.88
|
|
81
|
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
|
Eur Heart J
|
2011
|
0.87
|
|
82
|
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
|
Am Heart J
|
2006
|
0.87
|
|
83
|
Cardiology and the critical care crisis: a perspective.
|
J Am Coll Cardiol
|
2007
|
0.87
|
|
84
|
Noninvasive, medical management for non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2008
|
0.86
|
|
85
|
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
|
Ann Intern Med
|
2013
|
0.86
|
|
86
|
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration.
|
Am Heart J
|
2011
|
0.86
|
|
87
|
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.
|
Am Heart J
|
2011
|
0.86
|
|
88
|
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
|
J Am Heart Assoc
|
2014
|
0.85
|
|
89
|
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I.
|
Am Heart J
|
2005
|
0.85
|
|
90
|
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Int J Cardiol
|
2008
|
0.85
|
|
91
|
Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.
|
J Thromb Thrombolysis
|
2008
|
0.84
|
|
92
|
Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.
|
J Cardiovasc Transl Res
|
2010
|
0.84
|
|
93
|
The pharmacology of novel oral anticoagulants.
|
J Thromb Thrombolysis
|
2014
|
0.84
|
|
94
|
The pharmacogenetics of antiplatelet agents: towards personalized therapy?
|
Nat Rev Cardiol
|
2011
|
0.84
|
|
95
|
DVT: a new era in anticoagulant therapy.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.84
|
|
96
|
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
|
J Am Coll Cardiol
|
2012
|
0.84
|
|
97
|
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.83
|
|
98
|
Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
|
Eur Heart J
|
2008
|
0.83
|
|
99
|
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II.
|
Am Heart J
|
2005
|
0.83
|
|
100
|
Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions.
|
J Thromb Thrombolysis
|
2006
|
0.83
|
|
101
|
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
|
Am Heart J
|
2009
|
0.83
|
|
102
|
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation.
|
J Thromb Thrombolysis
|
2013
|
0.83
|
|
103
|
Clopidogrel use and bleeding after coronary artery bypass graft surgery.
|
Am Heart J
|
2008
|
0.82
|
|
104
|
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).
|
Circ Cardiovasc Genet
|
2015
|
0.82
|
|
105
|
Apixaban: an emerging oral factor Xa inhibitor.
|
J Thromb Thrombolysis
|
2010
|
0.82
|
|
106
|
A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.
|
Crit Pathw Cardiol
|
2012
|
0.81
|
|
107
|
Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.
|
J Am Coll Cardiol
|
2012
|
0.81
|
|
108
|
Circadian variations in acute myocardial infarction: patients or health care delivery?
|
J Am Coll Cardiol
|
2003
|
0.81
|
|
109
|
Hemostasis and thrombosis in older adults.
|
J Thromb Thrombolysis
|
2009
|
0.81
|
|
110
|
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
|
Clin Chem
|
2013
|
0.81
|
|
111
|
Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes.
|
Thromb Haemost
|
2016
|
0.80
|
|
112
|
Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.
|
J Thromb Thrombolysis
|
2003
|
0.80
|
|
113
|
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
|
Thromb Haemost
|
2014
|
0.80
|
|
114
|
Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
|
Circulation
|
2010
|
0.80
|
|
115
|
Aspirin and the prevention of venous thromboembolism.
|
N Engl J Med
|
2012
|
0.80
|
|
116
|
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
|
Thromb Haemost
|
2012
|
0.80
|
|
117
|
Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database.
|
Am Heart J
|
2013
|
0.80
|
|
118
|
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
|
Circulation
|
2002
|
0.80
|
|
119
|
Emerging paradigms in arterial thrombosis.
|
J Thromb Thrombolysis
|
2014
|
0.79
|
|
120
|
To bridge or not to bridge: these are the questions.
|
J Thromb Thrombolysis
|
2012
|
0.79
|
|
121
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
122
|
Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke.
|
Circulation
|
2002
|
0.79
|
|
123
|
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
|
Pharmacogenomics
|
2012
|
0.79
|
|
124
|
Inhibitors of platelet adhesion.
|
Circulation
|
2009
|
0.79
|
|
125
|
Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.
|
Platelets
|
2008
|
0.79
|
|
126
|
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
|
J Thromb Thrombolysis
|
2012
|
0.79
|
|
127
|
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
|
EuroIntervention
|
2015
|
0.79
|
|
128
|
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
|
Am Heart J
|
2002
|
0.78
|
|
129
|
Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.
|
J Thromb Thrombolysis
|
2014
|
0.78
|
|
130
|
Antiplatelet therapy in prevention of cardio- and venous thromboembolic events.
|
J Thromb Thrombolysis
|
2014
|
0.78
|
|
131
|
Platelet activation and its patient-specific consequences.
|
Thromb Res
|
2007
|
0.78
|
|
132
|
Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.78
|
|
133
|
Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee.
|
J Thromb Thrombolysis
|
2005
|
0.78
|
|
134
|
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.
|
Circ Cardiovasc Interv
|
2012
|
0.78
|
|
135
|
Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.
|
Cardiovasc Ther
|
2011
|
0.78
|
|
136
|
Stroke prevention in atrial fibrillation.
|
Cardiovasc Drugs Ther
|
2011
|
0.78
|
|
137
|
Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.
|
Mol Ther
|
2011
|
0.77
|
|
138
|
Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).
|
Am J Cardiol
|
2009
|
0.77
|
|
139
|
Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.
|
J Thromb Thrombolysis
|
2007
|
0.77
|
|
140
|
Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2010
|
0.77
|
|
141
|
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
|
Circulation
|
2013
|
0.77
|
|
142
|
PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
|
Handb Exp Pharmacol
|
2012
|
0.77
|
|
143
|
Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
|
Drugs
|
2010
|
0.77
|
|
144
|
Oral factor Xa inhibitors for the long-term management of ACS.
|
Nat Rev Cardiol
|
2012
|
0.77
|
|
145
|
The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.
|
Thromb Res
|
2010
|
0.76
|
|
146
|
Emerging paradigms, platforms, and unifying themes in biomarker science.
|
J Am Coll Cardiol
|
2007
|
0.76
|
|
147
|
Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function.
|
Ann Acad Med Singapore
|
2010
|
0.76
|
|
148
|
The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.
|
J Thromb Thrombolysis
|
2013
|
0.76
|
|
149
|
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
|
J Thromb Thrombolysis
|
2002
|
0.76
|
|
150
|
Antithrombotic therapy: new areas to understand efficacy and bleeding.
|
Expert Opin Ther Targets
|
2014
|
0.76
|
|
151
|
Warfarin-induced vasculopathy.
|
J Thromb Thrombolysis
|
2007
|
0.76
|
|
152
|
Identification and treatment of arterial thrombophilia.
|
Curr Treat Options Cardiovasc Med
|
2008
|
0.76
|
|
153
|
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients.
|
Am Heart J
|
2010
|
0.75
|
|
154
|
The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort.
|
Eur Heart J
|
2005
|
0.75
|
|
155
|
Advancing biomarker science in the 21st century.
|
Circ Cardiovasc Interv
|
2009
|
0.75
|
|
156
|
Thrombotic preparedness in aging: a translatable construct for thrombophilias?
|
J Thromb Thrombolysis
|
2007
|
0.75
|
|
157
|
Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy.
|
Ann Neurol
|
2008
|
0.75
|
|
158
|
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
|
Stroke
|
2013
|
0.75
|
|
159
|
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.
|
Circulation
|
2006
|
0.75
|
|
160
|
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research.
|
J Thromb Thrombolysis
|
2013
|
0.75
|
|
161
|
When guidelines collide...
|
Am Heart J
|
2004
|
0.75
|
|
162
|
A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application.
|
Thromb Res
|
2010
|
0.75
|
|
163
|
Nucleic acid aptamers as adjuncts to vaccine development.
|
Curr Opin Mol Ther
|
2006
|
0.75
|
|
164
|
A thought experiment in contemporary drug development: informed bench-to-bedside strategies.
|
J Am Heart Assoc
|
2013
|
0.75
|
|
165
|
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.
|
J Thromb Thrombolysis
|
2014
|
0.75
|
|
166
|
Emergence of factor IXa as a target for pharmacologic inhibition: editors page.
|
J Thromb Thrombolysis
|
2007
|
0.75
|
|
167
|
Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy.
|
Clin Cardiol
|
2004
|
0.75
|
|
168
|
Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil.
|
J Thromb Thrombolysis
|
2009
|
0.75
|
|
169
|
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications.
|
Circulation
|
2002
|
0.75
|
|
170
|
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
|
Am Heart J
|
2004
|
0.75
|
|
171
|
[Hematologic diseases: from within the heart].
|
Rev Esp Cardiol
|
2011
|
0.75
|
|
172
|
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
|
Thromb Haemost
|
2004
|
0.75
|
|
173
|
Platelet-mediated thrombosis and drug-eluting stents.
|
Circ Cardiovasc Interv
|
2011
|
0.75
|
|
174
|
Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?
|
Curr Cardiol Rep
|
2010
|
0.75
|
|
175
|
[Recent advances in atherothrombotic diseases].
|
Recenti Prog Med
|
2006
|
0.75
|
|
176
|
How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?
|
Curr Treat Options Cardiovasc Med
|
2011
|
0.75
|
|
177
|
Economic assessment of thrombocytopenia: CATCH Registry.
|
J Med Syst
|
2010
|
0.75
|
|
178
|
The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes.
|
J Thromb Thrombolysis
|
2016
|
0.75
|
|
179
|
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
|
Am Heart J
|
2012
|
0.75
|
|
180
|
Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2010
|
0.75
|
|
181
|
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
|
J Thromb Thrombolysis
|
2012
|
0.75
|
|
182
|
Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.
|
Am Heart J
|
2009
|
0.75
|
|
183
|
Oral anticoagulants in older adults with atrial fibrillation.
|
J Thromb Thrombolysis
|
2013
|
0.75
|
|
184
|
Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
|
Adv Cardiol
|
2012
|
0.75
|
|
185
|
A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.
|
Platelets
|
2009
|
0.75
|
|
186
|
The effect of temperature variation in vitro on platelet-leukocyte interactions and individual prothrombotic potential.
|
J Thromb Thrombolysis
|
2004
|
0.75
|
|
187
|
Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial.
|
J Invasive Cardiol
|
2013
|
0.75
|
|
188
|
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
|
J Thromb Thrombolysis
|
2013
|
0.75
|
|
189
|
Atherothrombotic disorders: new insights from hematology.
|
Circulation
|
2005
|
0.75
|
|
190
|
Pharmacogenetics of antiplatelet therapy.
|
Curr Atheroscler Rep
|
2014
|
0.75
|
|
191
|
Warfarin in vulnerable older adults with atrial fibrillation.
|
J Thromb Thrombolysis
|
2009
|
0.75
|
|
192
|
The unmet need for philanthropic funding of early career cardiovascular investigators.
|
J Thromb Thrombolysis
|
2014
|
0.75
|
|
193
|
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.
|
J Thromb Thrombolysis
|
2012
|
0.75
|
|
194
|
Modulating atherothrombosis: is there a place for vaccines in global prevention strategies?
|
J Thromb Thrombolysis
|
2006
|
0.75
|
|
195
|
Intramural hematoma of the thoracic aorta in a woman with neurofibromatosis.
|
Ann Thorac Surg
|
2002
|
0.75
|
|
196
|
Early career investigator's circle: identifying and nurturing the next generation of scientists and scientific writers.
|
J Thromb Thrombolysis
|
2008
|
0.75
|
|
197
|
Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin.
|
Am J Cardiol
|
2009
|
0.75
|